Autor. studio interv. profit dal titolo:“A phase III,multicenter,randomized,open-label study evaluating the efficacy and safety of inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with hormone receptor-positive,her2-negative,pik3ca mutated,locally advanced or metastatic breast cancer who progressed during or after cdk4/6 inhibitor and endocrine combination therapy-WO43919” INAVO121–Rif 14-22 EM-Resp Dr.ssa Francesca Martella-SOC Oncologia Medica San Giuseppe Empoli FI.
Allegato non firmabile Allegato non firmabile 08-05-24- Allegato non firmabile Allegato non firmabile 08-05-24
- Allegato non firmabile Allegato non firmabile 08-05-24
Atto firmato Atto firmato 08-05-24- Atto non firmato Atto non firmato 08-05-24
- Frontespizio Frontespizio 08-05-24
